AbCellera Biologics Inc. (ABCL) Ownership
ABCL ownership summary
as of October 18, 2026- Institutions
- 36.8% of shares outstanding
- Insiders
- 21.74% of shares outstanding
- Shares outstanding
- 324.0M
- Float
- 209.0M shares available to trade
- Short interest
- 12.78% 32.5M shares short
- Days to cover
- 7.04 short interest down 4.2% vs prior month
- Institutions 36.77%
- Insiders 21.74%
- Other investors 41.50%
ABCL top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Baker Bros Advisors LP | 10.19% | 33.0M | $389.5M | +2.7M (+9.0%) | June 30, 2026 |
| 2 | Capital World Investors | 4.19% | 13.6M | $160.3M | +227,253 (+1.7%) | June 30, 2026 |
| 3 | Two Sigma Investments LLC | 3.22% | 10.4M | $123.2M | −124,634 (−1.2%) | June 30, 2026 |
| 4 | TD Waterhouse Canada Inc | 2.95% | 9.6M | $112.9M | +3,490 (+0.0%) | June 30, 2026 |
| 5 | Bank of America Corp | 1.90% | 6.1M | $72.5M | +3.1M (+104.7%) | June 30, 2026 |
| 6 | UBS Asset Mgmt Americas Inc | 1.33% | 4.3M | $50.9M | −3.3M (−43.0%) | June 30, 2026 |
| 7 | ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 1.27% | 4.1M | $48.4M | — | June 30, 2026 |
| 8 | BlackRock Inc | 1.17% | 3.8M | $44.9M | −234,927 (−5.8%) | June 30, 2026 |
| 9 | Driehaus Capital Management LLC | 0.88% | 2.9M | $33.8M | −1.2M (−28.8%) | June 30, 2026 |
| 10 | Tudor Investment Corp Et AL | 0.64% | 2.1M | $24.3M | −210,298 (−9.2%) | June 30, 2026 |
| 11 | Marshall Wace Asset Management Ltd | 0.59% | 1.9M | $22.4M | +1.5M (+428.9%) | June 30, 2026 |
| 12 | UBS Group AG | 0.58% | 1.9M | $22.1M | −2.3M (−55.6%) | June 30, 2026 |
| 13 | Morgan Stanley - Brokerage Accounts | 0.52% | 1.7M | $19.7M | −555,815 (−25.0%) | June 30, 2026 |
| 14 | T. Rowe Price Associates, Inc. | 0.49% | 1.6M | $18.7M | +1.6M (0.0%) | June 30, 2026 |
| 15 | Citadel Advisors Llc | 0.49% | 1.6M | $18.7M | +225,407 (+16.6%) | June 30, 2026 |
| 16 | NATIONAL BANK OF CANADA /FI/ | 0.38% | 1.2M | $14.5M | +1.2M (+88,415.0%) | June 30, 2026 |
| 17 | Arrowstreet Capital Limited Partnership | 0.32% | 1.0M | $12.3M | +1.0M (0.0%) | June 30, 2026 |
| 18 | Renaissance Technologies Corp | 0.31% | 991K | $11.7M | −519,700 (−34.4%) | June 30, 2026 |
| 19 | Counterpoint Mutual Funds, LLC | 0.30% | 972K | $11.5M | +971,643 (0.0%) | June 30, 2026 |
| 20 | State Street Corp | 0.23% | 731K | $8.6M | +1,149 (+0.2%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 11 holders added 12.7M shares and 8 cut 8.4M.
ABCL top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | American Funds SMALLCAP World A | 4.08% | 13.2M | $156.1M | −132,500 (−1.0%) | June 30, 2026 |
| 2 | iShares Biotechnology ETF | 0.60% | 1.9M | $23.0M | −14,736 (−0.8%) | September 30, 2026 |
| 3 | ACATIS Datini Valueflex Fonds A | 0.57% | 1.9M | $21.9M | — | August 31, 2026 |
| 4 | UBS Lux Dgtl Hlth Eq Fd seeding P acc | 0.39% | 1.3M | $14.9M | −505,397 (−28.6%) | June 30, 2026 |
| 5 | BlackRock Health Sciences Opps Inv A | 0.39% | 1.3M | $14.8M | +1.3M (0.0%) | August 31, 2026 |
| 6 | Franklin Biotechnology Discv A(acc)USD | 0.31% | 1.0M | $11.8M | +1.0M (0.0%) | August 31, 2026 |
| 7 | T. Rowe Price New Horizons | 0.30% | 973K | $11.5M | +152,019 (+18.5%) | August 31, 2026 |
| 8 | DNB Fund Disrpt Opps A EUR Acc | 0.21% | 677K | $8.0M | — | August 31, 2026 |
| 9 | iShares Genomics Immnlgy & Hlthcr ETF | 0.19% | 625K | $7.4M | +17,252 (+2.8%) | September 30, 2026 |
| 10 | Heptagon Driehaus US Micro Cap Eq C$ Acc | 0.19% | 617K | $7.3M | — | August 31, 2026 |
| 11 | State Street® SPDR® Ptf Dev Wld exUS ETF | 0.18% | 574K | $6.8M | — | September 30, 2026 |
| 12 | Franklin Biotechnology Discovery A | 0.17% | 537K | $6.3M | +536,800 (0.0%) | August 31, 2026 |
| 13 | American Funds IS® SMALLCAP World 1 | 0.11% | 360K | $4.2M | +359,753 (0.0%) | June 30, 2026 |
| 14 | iShares Healthcare Innov ETF USD Acc | 0.11% | 360K | $4.2M | +1,305 (+0.4%) | September 30, 2026 |
| 15 | BlackRock Advantage Small Cap Core Instl | 0.10% | 321K | $3.8M | −9,102 (−2.8%) | August 31, 2026 |
| 16 | iShares Nasdaq US Biotech ETF USD Acc | 0.08% | 265K | $3.1M | +2,204 (+0.8%) | September 30, 2026 |
| 17 | Fidelity Nasdaq Composite Index | 0.08% | 256K | $3.0M | +74,210 (+40.9%) | August 31, 2026 |
| 18 | Driehaus Micro Cap Growth USD | 0.08% | 247K | $2.9M | — | July 31, 2026 |
| 19 | Allianz Biotechnologie P EUR | 0.07% | 241K | $2.8M | +241,025 (0.0%) | August 31, 2026 |
| 20 | Handelsbanken Global Småb Index (A1 NOK) | 0.04% | 132K | $1.6M | −16,220 (−11.0%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ABCL insider transactions
latest 2| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-26 | Andrew Booth | Buy | $6.85 | 14,500 | $99,325 |
| 2023-05-26 | Holdings Ltd. Thermopylae | Buy | $6.52 | 153,000 | $997,560 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ABCL shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ABCL
Institutional investors own 36.8% of AbCellera Biologics's shares and insiders 21.74%. The largest holder is Baker Bros Advisors LP with 10.19% of the shares (33.0M), as of June 30, 2026. Among the top 20 institutions, 11 added shares and 8 reduced their stake in the latest filings. Short interest is 12.78% of the float, or 7.04 days of average trading volume. The share count rose 74.7% since 2018.
Related: ABCL analyst forecast, ABCL key metrics. See the ABCL stock overview for the latest quote and news.
ABCL ownership FAQ
Who owns the most AbCellera Biologics stock?
The largest shareholders of AbCellera Biologics are Baker Bros Advisors LP (10.19%), Capital World Investors (4.19%), Two Sigma Investments LLC (3.22%), TD Waterhouse Canada Inc (2.95%), Bank of America Corp (1.90%).
What percentage of AbCellera Biologics is owned by institutions?
Institutions hold 36.8% of AbCellera Biologics's shares outstanding; insiders hold 21.74%.
Which funds own AbCellera Biologics?
The largest fund holders of AbCellera Biologics are American Funds SMALLCAP World A (4.08%), iShares Biotechnology ETF (0.60%), ACATIS Datini Valueflex Fonds A (0.57%), UBS Lux Dgtl Hlth Eq Fd seeding P acc (0.39%), BlackRock Health Sciences Opps Inv A (0.39%).
What is AbCellera Biologics's short interest?
32.5M shares of AbCellera Biologics were sold short, 12.78% of the float; at the average daily volume it would take 7.04 days to cover.
Are insiders buying or selling AbCellera Biologics?
Of the latest 2 reported insider transactions in AbCellera Biologics (since May 26, 2023), 2 were purchases and 0 were sales.
How many shares of AbCellera Biologics are outstanding?
AbCellera Biologics has 324.0M shares outstanding, of which 209.0M are in the public float.